HC Wainwright reaffirmed their buy rating on shares of OptiNose (NASDAQ:OPTN - Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $5.00 price objective on the stock.
OptiNose Stock Performance
Shares of OPTN traded down $0.09 during mid-day trading on Wednesday, reaching $0.51. The company had a trading volume of 5,392,486 shares, compared to its average volume of 733,043. The company has a market capitalization of $76.47 million, a price-to-earnings ratio of -1.98 and a beta of -0.07. OptiNose has a 1-year low of $0.50 and a 1-year high of $2.10. The company's 50 day simple moving average is $0.77 and its 200 day simple moving average is $0.96.
Institutional Investors Weigh In On OptiNose
Several hedge funds and other institutional investors have recently made changes to their positions in OPTN. GSA Capital Partners LLP purchased a new stake in OptiNose in the 3rd quarter worth approximately $61,000. XTX Topco Ltd purchased a new position in OptiNose in the second quarter worth about $88,000. Squarepoint Ops LLC boosted its position in shares of OptiNose by 173.7% in the second quarter. Squarepoint Ops LLC now owns 171,610 shares of the company's stock worth $178,000 after purchasing an additional 108,903 shares during the period. Oracle Investment Management Inc. bought a new position in OptiNose during the first quarter valued at $474,000. Finally, Rice Hall James & Associates LLC lifted its position in shares of OptiNose by 15.4% during the third quarter. Rice Hall James & Associates LLC now owns 1,140,626 shares of the company's stock valued at $764,000 after buying an additional 152,435 shares during the last quarter. 85.60% of the stock is owned by institutional investors.
About OptiNose
(
Get Free Report)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Featured Stories
Before you consider OptiNose, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptiNose wasn't on the list.
While OptiNose currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
